MX2018013969A - Combinacion de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda. - Google Patents
Combinacion de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda.Info
- Publication number
- MX2018013969A MX2018013969A MX2018013969A MX2018013969A MX2018013969A MX 2018013969 A MX2018013969 A MX 2018013969A MX 2018013969 A MX2018013969 A MX 2018013969A MX 2018013969 A MX2018013969 A MX 2018013969A MX 2018013969 A MX2018013969 A MX 2018013969A
- Authority
- MX
- Mexico
- Prior art keywords
- combination
- pure
- receptor antagonist
- nmda
- receptor
- Prior art date
Links
- 229940099433 NMDA receptor antagonist Drugs 0.000 title abstract 2
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 title abstract 2
- 108091005435 5-HT6 receptors Proteins 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003751 serotonin 6 antagonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere al antagonista del receptor 5-HT6 puro o la sal o sales farmacéuticamente aceptables del mismo en combinación o como complementario de un antagonista del receptor NMDA y a su uso en el tratamiento de trastornos cognitivos. La invención también se refiere a la composición farmacéutica que contiene dicha combinación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641017203 | 2016-05-18 | ||
| PCT/IB2016/054674 WO2017199072A1 (en) | 2016-05-18 | 2016-08-03 | Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018013969A true MX2018013969A (es) | 2019-03-21 |
| MX378799B MX378799B (es) | 2025-03-11 |
Family
ID=56940099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013969A MX378799B (es) | 2016-05-18 | 2016-08-03 | Combinación de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11116764B2 (es) |
| EP (1) | EP3458040B1 (es) |
| JP (1) | JP6606298B2 (es) |
| KR (1) | KR102023748B1 (es) |
| CN (1) | CN109069449A (es) |
| AU (1) | AU2016407428B2 (es) |
| BR (1) | BR112018073396A2 (es) |
| CA (1) | CA3023828C (es) |
| DK (1) | DK3458040T3 (es) |
| EA (1) | EA036301B1 (es) |
| HK (1) | HK1258023A1 (es) |
| HR (1) | HRP20210640T1 (es) |
| HU (1) | HUE055083T2 (es) |
| IL (1) | IL262816B (es) |
| MX (1) | MX378799B (es) |
| NZ (1) | NZ747778A (es) |
| SG (1) | SG11201809725TA (es) |
| WO (1) | WO2017199072A1 (es) |
| ZA (1) | ZA201807311B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110799189A (zh) * | 2017-07-03 | 2020-02-14 | 苏文生命科学有限公司 | 纯5-ht6受体拮抗剂的新用途 |
| JP7556031B2 (ja) * | 2019-12-02 | 2024-09-25 | スヴェン・ライフ・サイエンシーズ・リミテッド | 認知症患者の行動心理学的症状の治療 |
| MD4069231T2 (ro) * | 2019-12-02 | 2025-10-31 | Suven Life Sciences Ltd | Combinații de masupirdină cu donepezil sau memantină pentru tratarea simptomelor comportamentale și psihologice la pacienți cu demență |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101544592B (zh) * | 2002-11-28 | 2013-08-21 | 苏文生命科学有限公司 | N-芳基磺酰-3-取代吲哚制备的替代方法 |
| WO2004055026A1 (en) * | 2002-12-18 | 2004-07-01 | Suven Life Sciences Limited | Tetracyclic 3-substituted indoles having serotonin receptor affinity |
| EP1902733A1 (en) * | 2006-09-19 | 2008-03-26 | Laboratorios Del Dr. Esteve, S.A. | Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity |
| WO2015083179A1 (en) | 2013-12-02 | 2015-06-11 | Suven Life Sciences Limited | Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate |
| EA031319B1 (ru) * | 2014-08-16 | 2018-12-28 | Сувен Лайф Сайенсиз Лимитед | Активный метаболит димезилатмоногидрата 1-[(2-бромфенил)сульфонил]-5-метокси-3-[(4-метил-1-пиперазинил)метил]-1h-индола и димезилатдигидратная соль активного метаболита |
-
2016
- 2016-08-03 MX MX2018013969A patent/MX378799B/es unknown
- 2016-08-03 WO PCT/IB2016/054674 patent/WO2017199072A1/en not_active Ceased
- 2016-08-03 EA EA201892583A patent/EA036301B1/ru unknown
- 2016-08-03 SG SG11201809725TA patent/SG11201809725TA/en unknown
- 2016-08-03 JP JP2018559283A patent/JP6606298B2/ja active Active
- 2016-08-03 HU HUE16766623A patent/HUE055083T2/hu unknown
- 2016-08-03 BR BR112018073396-2A patent/BR112018073396A2/pt not_active Application Discontinuation
- 2016-08-03 AU AU2016407428A patent/AU2016407428B2/en active Active
- 2016-08-03 KR KR1020187035901A patent/KR102023748B1/ko active Active
- 2016-08-03 HK HK19100394.1A patent/HK1258023A1/zh unknown
- 2016-08-03 NZ NZ747778A patent/NZ747778A/en unknown
- 2016-08-03 CA CA3023828A patent/CA3023828C/en active Active
- 2016-08-03 DK DK16766623.9T patent/DK3458040T3/da active
- 2016-08-03 US US16/097,458 patent/US11116764B2/en active Active
- 2016-08-03 CN CN201680085559.6A patent/CN109069449A/zh active Pending
- 2016-08-03 HR HRP20210640TT patent/HRP20210640T1/hr unknown
- 2016-08-03 EP EP16766623.9A patent/EP3458040B1/en active Active
-
2018
- 2018-10-31 ZA ZA2018/07311A patent/ZA201807311B/en unknown
- 2018-11-06 IL IL262816A patent/IL262816B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016407428A1 (en) | 2018-11-29 |
| EP3458040A1 (en) | 2019-03-27 |
| CA3023828A1 (en) | 2017-11-23 |
| IL262816B (en) | 2020-05-31 |
| JP2019516696A (ja) | 2019-06-20 |
| AU2016407428B2 (en) | 2019-11-21 |
| CN109069449A (zh) | 2018-12-21 |
| US20190175586A1 (en) | 2019-06-13 |
| EP3458040B1 (en) | 2021-01-27 |
| DK3458040T3 (da) | 2021-05-03 |
| EA036301B1 (ru) | 2020-10-23 |
| CA3023828C (en) | 2019-08-27 |
| JP6606298B2 (ja) | 2019-11-13 |
| MX378799B (es) | 2025-03-11 |
| WO2017199072A1 (en) | 2017-11-23 |
| SG11201809725TA (en) | 2018-12-28 |
| NZ747778A (en) | 2020-03-27 |
| US11116764B2 (en) | 2021-09-14 |
| KR20180136566A (ko) | 2018-12-24 |
| HRP20210640T1 (hr) | 2021-06-25 |
| IL262816A (en) | 2018-12-31 |
| HUE055083T2 (hu) | 2021-10-28 |
| HK1258023A1 (zh) | 2019-11-01 |
| KR102023748B1 (ko) | 2019-09-20 |
| ZA201807311B (en) | 2020-01-29 |
| EA201892583A1 (ru) | 2019-04-30 |
| BR112018073396A2 (pt) | 2019-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018003597A1 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores delrrk2 para el uso en el tratamiento de trastornos neurodegenerativos. | |
| CL2016001983A1 (es) | Compuestos aza bicíclicos como agonistas del receptor muscarínico m1 y/o m4 | |
| MX379110B (es) | Derivados de azaspiro como antagonistas de trpm8. | |
| CO2017002159A2 (es) | Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
| MX2017011206A (es) | Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer. | |
| UY37410A (es) | Antagonistas de trpv4 | |
| UY36224A (es) | Compuestos tricíclicos de imidazo-pirimidinona | |
| UY36003A (es) | Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina. | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| CL2019001329A1 (es) | Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso. | |
| CO2017001601A2 (es) | Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| CY1123013T1 (el) | Συνδυασμος των καθαρων ανταγωνιστων του υποδοχεα 5-ητ6 με τους αναστολεις της ακετυλοχολινεστερασης | |
| CL2016000884A1 (es) | Derivados de piperazina y su uso como medicamento. | |
| CL2019000027A1 (es) | Regímenes de dosificación de antagonistas de la lingo-1 y usos para el tratamiento de los trastornos desmielinizantes. | |
| MX2018013969A (es) | Combinacion de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda. | |
| MX2019010993A (es) | Derivados de tetrahidroquinolina como antagonistas del receptor p2x7. | |
| BR112018000568A2 (pt) | antagonistas do receptor 5-ht6 para uso no tratamento da doença de alzheimer com apatia como comorbidade | |
| ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| MX2018014184A (es) | Triple combinacion de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda. | |
| ECSP16094286A (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas | |
| UY36608A (es) | Derivados de indol | |
| EA201692426A1 (ru) | Комбинации зальтопрофена и миорелаксанта | |
| BR112016028081A2 (pt) | Novos compostos como agentes antituberculares | |
| MX2019001696A (es) | Combinacion de agonistas inversos de receptor de histamina-3 con inhibidores de acetilcolinesterasa. |